Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ferric Citrate→

Ferric Citrate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
3522-50-7
Molecular formula
C6H5FeO7
Molecular weight
244.94 g/mol
Drug class
Ferric iron–citrate complexphosphate-binding agent and iron source
Mechanism of action
Ferric iron binds dietary phosphate in the gastrointestinal tract, forming insoluble ferric-phosphate complexes that are eliminated in the faeces. The complex can also provide absorbable iron; these functions are product- and formulation-specific.
Indications / reported uses
  • Control of serum phosphorus in adults with chronic kidney disease on dialysis
  • Treatment of iron-deficiency anaemia in adults with chronic kidney disease not on dialysis under the applicable product indication; monitor iron indices and phosphate

Sources: US DailyMed — AURYXIA (ferric citrate) · US FDA prescribing information · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Ferric iron–citrate complex; phosphate-binding agent and iron source

Mechanism of action

Ferric iron binds dietary phosphate in the gastrointestinal tract, forming insoluble ferric-phosphate complexes that are eliminated in the faeces. The complex can also provide absorbable iron; these functions are product- and formulation-specific.

General use cases

  • Control of serum phosphorus in adults with chronic kidney disease on dialysis
  • Treatment of iron-deficiency anaemia in adults with chronic kidney disease not on dialysis under the applicable product indication; monitor iron indices and phosphate

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Ferric Citrate Environmental Risk Assessment (ERA) (the Ferric Citrate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.